Navigation Links
Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
Date:6/29/2009

HORSHAM, Pa., June 29 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit.

"We are pleased that the jury has ruled in our favor in the patent litigation case against Abbott," said Kim Taylor, President, Centocor Ortho Biotech Inc. The patent in question relates to the company's anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee.

"We are particularly gratified that the jury recognized our valuable intellectual property, finding our patent both valid and infringed. We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatment for patients with a number of immune mediated inflammatory diseases," Taylor added.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. The company was created when Ortho Biotech Inc. merged into Centocor, Inc., and Centocor, Inc. was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. For more information about Centocor Ortho Biotech, visit www.CentocorOrthoBiotech.com. Centocor Ortho Biotech is a wholly-owned subsidiary of Johnson & Johnson.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor Ortho Biotech Inc. and/or Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
3. GeneNews provides Centocor access to its osteoarthritis program
4. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
5. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
7. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
8. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
9. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. Pioneer(R) Surgical Technology, Inc. Wins Frost & Sullivans 2009 North American Orthopaedic Tissue Engineering Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 20, 2017 , ... ... to the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new ... clinical and scientific consultants and contractors. This is the latest step in G&L’s ...
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has ... pioneering medical device for the treatment of Age-Related Macular Degeneration. , The company’s ... global regulatory consultancy that helps companies like ours secure government approvals for their ...
(Date:1/21/2017)... 20, 2017 Bioptix, Inc. (Nasdaq: ... that on January 14, 2017 the Board of Directors ... Company will terminate certain employees associated with the September ... Company commenced terminations on January 16, 2017 and terminations ... Company may pay severance benefits in certain circumstances of ...
(Date:1/21/2017)... Jan. 21, 2017   Boston Biomedical , an ... to target cancer stemness pathways, today presented data from ... at the 2017 American Society of Clinical Oncology (ASCO) ... . In a Phase Ib/II study ... to inhibit cancer stemness pathways by targeting STAT3 – ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
Breaking Biology News(10 mins):